| 1/12 (%) | 2/12 (%) | 3/12 (%) | 4/12 (%) | 5/12 (%) | 6/12 (%) | 7/12 (%) | 8/12 (%) | 9/12 (%) | 10/12 (%) | 11/12 (%) | 12/12 (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | 1 (5%) | 1 (5%) | Â | Â | Â | Â | Â | Â | 2 (11%) | 1 (5%) | Â | 2 (11%) |
Surveillance | Â | Â | Â | Â | Â | Â | Â | 1 (5%) | 1 (5%) | 3 (11%) | 3 (16%) | 3 (16%) |
Total for all participants (N = 19) | 1 (5%) | 1 (5%) |  |  |  |  | 1 (5%) | 1 (5%) | 3 (16%) | 4 (21%) | 3 (16%) | 5 (26%) |
Lost to attrition | 1 (5%) | 1 (5%) | Â | Â | Â | Â | 1 (5%) | Â | Â | 2 (11%) | Â | Â |
Total at study completion (n = 14) | 0 (0%) | 0 (0%) |  |  |  |  | 0 (0%) | 1 (5%) | 3 (16%) | 2 (11%) | 3 (16%) | 5 (26%) |